Welcome to drugdiscoveryanddevelopment.co.uk
Click to listen highlighted text!
Welcome to drugdiscoveryanddevelopment.co.uk
Subscribe to newsletter
Facebook
Linkedin
X
Youtube
Linkedin
Twitter
Youtube
Tue 22 September 2026
A Pharma Press Global company
Subscribe to DDD newsletter
Search
Drug Discovery and Development
Drug Discovery
Investigational New Drug application
Phase 1-2 trials
Phase 3 trials
Approvals
Finance
Conferences
Journal
Drug Discovery
Investigational New Drug application
Phase 1-2 trials
Phase 3 trials
Approvals
Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials
9 September 2026
GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data
9 September 2026
New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...
8 September 2026
Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM
8 September 2026
Tezspire demonstrates positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
8 September 2026
Products
CDMO
CRO
Pharma Press Global publications
Drug Discovery and Development journal is now live
Journal
Drug Discovery and Development (June-September) has launched. Dedicated to the needs of biotech and pharma leaders, this journal of pharma intelligence...
Read more
Exclusive preview to BIO International Convention 2026
Journal
Drug Discovery and Development journal launched and includes an exclusive preview to the prestigious BIO International Convention, taking place...
Read more
Click to return to the main website
Click to listen highlighted text!